drugset / Trial / NCT05007613
Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Phase 2
Completed
24 enrolled
National Taiwan University Hospital
Ipsen · collabRoche Pharma AG · collab
NaSingle-groupOpen-labelTreatment
Summary
To demonstrate that combination of cabozantinib and atezolizumab is safe and efficacious in patients with recurrent/metastatic esophageal squamous cell carcinoma.
Timeline
- Start
- 2021-06-23
- Primary completion
- 2024-07-17
- Completion
- 2024-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Cabozantinib | Small molecule | 40 mg | Oral |